Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Regeneron Pharmaceuticals Analyst Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Regeneron Pharmaceuticals Analyst Ratings
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)
Regeneron Pharmaceuticals Analyst Ratings
Revolution Medicines Analyst Ratings
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
Barclays Remains a Buy on Revolution Medicines (RVMD)